"We believe in the first half we would continue to make losses, but in the fourth quarter or second half we will be in a position to break-even or even turn a profit," said Lu in a media conference call.
Singapore-listed Biosensors also said on Friday it has received European regulatory approval for its BioMatrix heart stents.
No comments:
Post a Comment